Medical advancements that have significantly extended the lives of cancer patients are bringing a secondary challenge to the forefront: the rise of therapy-related acute myeloid leukemia. A new population-based study from Japan indicates that as more people survive their primary cancers, there is a gradual increase in the rates of this aggressive blood cancer, which develops as a complication of previous life-saving treatments.
The research, published in the peer-reviewed journal Cancer by the American Cancer Society, analyzed three decades of patient data to track how chemotherapy and radiation can inadvertently damage DNA, leading to the development of tAML. The findings suggest a shift in the landscape of post-cancer complications, with a notable increase in cases following breast cancer treatment.
Between 1990 and 2020, investigators using data from the Osaka Cancer Registry found that the annual incidence of therapy-related acute myeloid leukemia rose from 0.13 per 100,000 population to 0.36 per 100,000 population. While the overall number of cases remains small relative to the general population, the proportion of tAML cases among all acute myeloid leukemia diagnoses nearly doubled over the 30-year period.
As a board-certified physician, I have seen how the “success” of modern oncology creates a new cohort of long-term survivors. While the primary goal of treatment is always the eradication of the first tumor, the systemic nature of many chemotherapies means that healthy bone marrow cells can be collateral damage, potentially seeding the ground for leukemia years later.
Understanding the Mechanism of Therapy-Related AML
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. When it is classified as “therapy-related,” it means the disease was triggered by previous medical interventions—specifically cytotoxic chemotherapy or ionizing radiation. These treatments perform by damaging the DNA of rapidly dividing cancer cells, but they can as well cause mutations in hematopoietic stem cells.
These mutations may remain dormant for years. However, once the genetic damage reaches a critical threshold, the bone marrow begins producing abnormal myeloid blasts that crowd out healthy blood cells. This makes tAML particularly dangerous because the patient’s bone marrow has often already been compromised by previous rounds of treatment, making the leukemia more resistant to further chemotherapy.
The study analyzed a total of 9,841 patients diagnosed with AML in the Osaka region. Of these, 636 patients—approximately 6.5%—were diagnosed with the therapy-related form of the disease.
Shifting Patterns in Primary Cancers
The researchers observed that the types of primary cancers preceding tAML have shifted over time. While blood-related cancers remain the most frequent precursor, there has been a prominent increase in cases linked to breast cancer treatments. Conversely, cases following gastric cancer treatments have decreased.
| Primary Cancer Type | Percentage of tAML Cases |
|---|---|
| Blood Cancers | 23.1% |
| Breast Cancer | 14.6% |
| Colorectal Cancer | 11.5% |
| Gastric Cancer | 8.7% |
This shift likely reflects changes in the prevalence of certain cancers and the evolution of treatment protocols. The increase in breast cancer-related tAML may be tied to the long-term survival rates of patients treated with alkylating agents or other chemotherapy regimens that, while effective at preventing breast cancer recurrence, carry a known risk of secondary malignancies.
Kenji Kishimoto, MD, PhD, lead author from the Osaka International Cancer Institute, noted that the study provides an important step towards better understanding how the nature of tAML is changing with the increasing number of cancer survivors.
The Impact on Long-Term Survivorship
For patients and clinicians, these findings highlight the necessity of lifelong surveillance for cancer survivors. The “survivorship” phase of cancer care is no longer just about monitoring for the return of the original tumor, but also about watching for “late effects” of treatment.
The challenge for oncologists is the delicate balance of risk. The therapies used to treat breast or colorectal cancer are essential for survival. However, the risk of developing tAML is a real, albeit statistically small, possibility. Understanding which specific drugs or radiation doses correlate most strongly with these outcomes is the next critical step in refining precision medicine.
Currently, the medical community is focusing on several key areas to mitigate these risks:
- Drug Optimization: Moving toward targeted therapies that attack cancer cells more specifically, reducing the “off-target” DNA damage to bone marrow.
- Enhanced Monitoring: Implementing more frequent blood counts and marrow screenings for high-risk survivors.
- Personalized Risk Profiling: Identifying genetic markers that make certain individuals more susceptible to therapy-induced mutations.
Because tAML is often more aggressive than de novo AML (leukemia that occurs without prior treatment), early detection is the only way to improve outcomes. When detected early, patients may be candidates for stem cell transplants or newer, less toxic targeted agents.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their primary healthcare provider or oncologist regarding their specific treatment history and screening needs.
The research team in Osaka will continue to monitor the registry data to determine if the trend of increasing tAML incidence persists as newer generations of immunotherapy and targeted biologicals replace traditional chemotherapy. Further publications regarding the specific chemotherapy agents most linked to these increases are expected as the data is further stratified.
We invite you to share your thoughts or questions about cancer survivorship and long-term health monitoring in the comments below.
Worth a look
